Novo Nordisk A/S (NYSE:NVO) shared data from its renal outcomes study, FLOW, on Friday. The study evaluated once-weekly injectable Ozempic for the treatment of type 2 diabetes.
Get notified with breaking news, our articles and more!
Follow us
The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study included 3,533 patients with a median follow-up period of 3.4 years.
In March, the company released headline data demonstrating a 24% reduction in kidney disease progression and cardiovascular and renal mortality.
The data was shared at the European Renal Association Congress.
Detailed data showed that secondary endpoints also saw significant improvements with semaglutide. In particular, the total slope of the estimated glomerular filtration rate (eGFR) was slower by 1.16 ml/min/1.73m2/year, the risk of major cardiovascular events decreased by 18% and the risk of mortality for all causes was reduced by 20%.
The professor Vlado Perkovic presented the findings for the first time today at the 61st ERA Congress.
“The use of semaglutide in people with type 2 diabetes and chronic kidney disease may lower the risk of major renal outcomes and reduce the risk of cardiovascular events, cardiovascular death and death from all causes,” Perkovic said. “These benefits mean a profound clinical impact that saves kidneys, hearts and lives for patients with type 2 diabetes and chronic kidney disease. Furthermore, the reassuring safety results further support the strong potential value of semaglutide in this population.”
The findings promise to reshape treatment strategies for those at high risk of diabetes-related complications, offering a new avenue for protecting the kidneys and cardiovascular system, Perkovic added.
Novo Nordisk stock price
NVO shares were down 0.67% at $134.66 at last check on Friday.
For more updates on this topic, add Benzinga Italy to your favorites or follow us on our social channels: X And Facebook.
Receive exclusive insights into market movements 30 minutes before other traders
The 14-day free trial of Benzinga Pro, available in English only, gives you access to exclusive information so you can receive actionable trading signals before millions of other traders. CLICK HERE to start your free trial.
Image: Shutterstock
